Infection based large scale production platform for rAAV gene therapy vectors

PRINCIPAL INVESTIGATOR:
PD Dr. Stefan Weger
Charité

ATMP
Gene Therapy

2021

Track 2

SUMMARY

Gene transfer vectors have developed into the leading platform for gene therapeutic treatments of numerous human diseases and several rAAV vectors have already been approved for commercialization.
The current methods for rAAV production represent a bottleneck and render the generation of these therapeutics extremely expensive.
This projects aims at developing a new method which allows a more efficient production of clinically applicable rAAVs, leading to increased availability and reduced costs for gene therapies.

PROJECT GOALS

- Establishment of universal platform for large-scale rAAV production
- Identification of industrial partner for co-development
- Extension of the platform to different rAAV serotypes

LONG-TERM GOALS

- License to Biotech company or startup foundation
- Perform phase I clinical trial